CN109890957A - 非遗传修饰的包膜病毒 - Google Patents

非遗传修饰的包膜病毒 Download PDF

Info

Publication number
CN109890957A
CN109890957A CN201780056649.7A CN201780056649A CN109890957A CN 109890957 A CN109890957 A CN 109890957A CN 201780056649 A CN201780056649 A CN 201780056649A CN 109890957 A CN109890957 A CN 109890957A
Authority
CN
China
Prior art keywords
virus
peptide
seq
tumor
hsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780056649.7A
Other languages
English (en)
Chinese (zh)
Inventor
文森佐·史汝乐
克里斯蒂安·卡帕索
埃尔科·耶洛玛基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grace Therapy Inc
Original Assignee
Grace Therapy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grace Therapy Inc filed Critical Grace Therapy Inc
Publication of CN109890957A publication Critical patent/CN109890957A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780056649.7A 2016-09-27 2017-09-06 非遗传修饰的包膜病毒 Pending CN109890957A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1616365.1A GB201616365D0 (en) 2016-09-27 2016-09-27 Non-genetic modification of enveloped viruses
GB1616365.1 2016-09-27
PCT/EP2017/072366 WO2018059896A1 (en) 2016-09-27 2017-09-06 Non-genetic modification of enveloped viruses

Publications (1)

Publication Number Publication Date
CN109890957A true CN109890957A (zh) 2019-06-14

Family

ID=57539741

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780056649.7A Pending CN109890957A (zh) 2016-09-27 2017-09-06 非遗传修饰的包膜病毒

Country Status (12)

Country Link
US (1) US10982194B2 (https=)
EP (1) EP3519565A1 (https=)
JP (2) JP7258746B2 (https=)
KR (1) KR102599401B1 (https=)
CN (1) CN109890957A (https=)
AU (2) AU2017337753B2 (https=)
BR (1) BR112019005825A2 (https=)
CA (1) CA3035104A1 (https=)
GB (1) GB201616365D0 (https=)
RU (1) RU2760521C2 (https=)
WO (1) WO2018059896A1 (https=)
ZA (1) ZA201902388B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114302740A (zh) * 2019-05-24 2022-04-08 瓦洛治疗公司 病毒载体

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020252039A1 (en) * 2019-06-12 2020-12-17 Biontech Us Inc. Neoantigen compositions and uses thereof
US20220305099A1 (en) * 2019-08-27 2022-09-29 Turnstone Biologics Corp. Methods for inducing an immune response against neoantigens
GB202013834D0 (en) * 2020-09-03 2020-10-21 Valo Therapeutics Oy PeptiVAX therapy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271620A1 (en) * 2002-02-12 2005-12-08 Brown Susanne M Herpes simplex virus complex
CN1764719A (zh) * 2003-03-26 2006-04-26 赛托斯生物技术公司 Melan－a肽类似物－病毒样颗粒偶联物
JP2008136381A (ja) * 2006-11-30 2008-06-19 Japan Health Science Foundation 改変型アデノウイルスベクター及びその作製方法
WO2008103762A1 (en) * 2007-02-20 2008-08-28 The University Of Chicago Targeting of herpes simplex virus to specific receptors
WO2009144755A1 (en) * 2008-05-29 2009-12-03 Alma Mater Studiorum - Universita' Di Bologna Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof
US20140349944A1 (en) * 2013-05-23 2014-11-27 Musc Foundation For Research Development Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1257286C (zh) 1998-08-27 2006-05-24 森泰莱昂公司 用于递送异源基因的定向腺病毒载体
MXPA01005389A (es) * 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
IL145899A0 (en) * 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses
CN100352921C (zh) 1999-05-06 2007-12-05 威克福雷大学 用于鉴定引起免疫反应的抗原的组合物和方法
CN101024842A (zh) * 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
WO2004000220A2 (en) 2002-06-21 2003-12-31 Genetix Pharmaceuticals, Inc. Methods for purifying viral particles for gene therapy
HRP20120845T1 (hr) * 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
WO2005060541A2 (en) 2003-12-01 2005-07-07 Wisconsin Alumni Research Foundation Peptides and methods for inducing cellular resistance to infection
KR101157694B1 (ko) * 2003-12-17 2012-06-20 와이어쓰 엘엘씨 면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
WO2009117656A2 (en) 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
EP2349296B1 (en) * 2008-08-21 2017-04-05 Ottawa Hospital Research Institute Engineered synergistic oncolytic viral symbiosis
ES2335077B1 (es) 2008-12-30 2011-02-02 Instituto Aragones De Ciencias De La Salud Formulaciones para el recubrimiento y transporte de diversos elementos hacia los tumores.
US8609392B2 (en) * 2009-05-12 2013-12-17 Transgene S.A. Method for orthopoxvirus production and purification
US20130243731A1 (en) 2010-09-24 2013-09-19 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies
US20140140962A1 (en) 2011-04-29 2014-05-22 The Research Foundation Of State University Of New York Viruses modified with unnatural moieties and methods of use thereof
RS65104B1 (sr) 2013-08-22 2024-02-29 Univ Pittsburgh Commonwealth Sys Higher Education Onkolitičke imunoterapije
BR112016009465A8 (pt) * 2013-10-28 2018-01-30 Univ Pittsburgh Commonwealth Sys Higher Education vetor de hsv oncolítico.
US10799568B2 (en) 2014-05-19 2020-10-13 Valo Therapeutics Oy Modified adenoviruses for cancer vaccines development

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271620A1 (en) * 2002-02-12 2005-12-08 Brown Susanne M Herpes simplex virus complex
CN1764719A (zh) * 2003-03-26 2006-04-26 赛托斯生物技术公司 Melan－a肽类似物－病毒样颗粒偶联物
JP2008136381A (ja) * 2006-11-30 2008-06-19 Japan Health Science Foundation 改変型アデノウイルスベクター及びその作製方法
WO2008103762A1 (en) * 2007-02-20 2008-08-28 The University Of Chicago Targeting of herpes simplex virus to specific receptors
WO2009144755A1 (en) * 2008-05-29 2009-12-03 Alma Mater Studiorum - Universita' Di Bologna Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof
US20140349944A1 (en) * 2013-05-23 2014-11-27 Musc Foundation For Research Development Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CRISTIAN CAPASSO ET AL.,: ""Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma"", 《ONCOIMMUNOLOGY》 *
SUSANNE HEIDER ET AL.,: ""Biomedical applications of glycosylphosphatidylinositol-anchored proteins"", 《JOURNAL OF LIPID RESEARCH》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114302740A (zh) * 2019-05-24 2022-04-08 瓦洛治疗公司 病毒载体

Also Published As

Publication number Publication date
NZ751251A (en) 2025-03-28
AU2017337753A1 (en) 2019-03-21
JP2019532631A (ja) 2019-11-14
JP2023029997A (ja) 2023-03-07
KR102599401B1 (ko) 2023-11-06
US10982194B2 (en) 2021-04-20
AU2023237201A1 (en) 2023-12-14
AU2017337753B2 (en) 2023-09-28
US20200010811A1 (en) 2020-01-09
RU2019110407A (ru) 2020-10-29
EP3519565A1 (en) 2019-08-07
RU2760521C2 (ru) 2021-11-26
BR112019005825A2 (pt) 2019-06-11
GB201616365D0 (en) 2016-11-09
JP7258746B2 (ja) 2023-04-17
ZA201902388B (en) 2020-10-28
WO2018059896A1 (en) 2018-04-05
AU2023237201B2 (en) 2025-06-05
CA3035104A1 (en) 2018-04-05
RU2019110407A3 (https=) 2021-05-13
KR20190053260A (ko) 2019-05-17

Similar Documents

Publication Publication Date Title
CA3162930A1 (en) Recombinant polypeptides for programming extracellular vesicles
AU2023237201B2 (en) Non-genetic modification of enveloped viruses
Lachmann et al. Raising antibodies by coupling peptides to PPD and immunizing BCG‐sensitized animals
Rueda et al. Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines
JP2018529320A5 (https=)
CN107073089A (zh) 用于癌症疫苗的包被的溶瘤腺病毒
Zhang et al. Impact of dose, route, and composition on the immunogenicity of immune polyelectrolyte multilayers delivered on gold templates
US10925960B2 (en) Antigen delivery system
EP4210734A1 (en) Heterologous prime boost vaccine
CN110526976A (zh) 一种靶向psma的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CN114302740A (zh) 病毒载体
Skea et al. The immunotargeting approach to adjuvant-independent immunization with influenza haemagglutinin
US20240226279A1 (en) Human anti-coronavirus peptide vaccines and methods of their use
CN1930184B (zh) 新型tat复合物，及包含其的疫苗
CN110526990A (zh) 靶向cd30的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
White et al. Increased adjuvant activity of minimal CD8 T cell peptides incorporated into lipid‐core‐peptides
CN103360465B (zh) 胞质多聚腺苷酸化成分结合蛋白4的hla-a*0201限制性ctl表位及其应用
CN119156343A (zh) 搭载肽的载体系统及其用途
CN120478612A (zh) 一种基于t4-蛋白的三聚体疫苗平台及其应用
CN120789242A (zh) 一种egfr l858r突变特异性长肽疫苗及其应用
Liu et al. The efficacy of chimeric vaccines constructed with PEP-1 and Ii-Key linking to a hybrid epitope from heterologous viruses
Schultz et al. peptide Assembly on the Membrane Determines the HIV-1 Inhibitory Activity of Dual-Targeting Fusion Inhibitor Peptides
CN110526986A (zh) 靶向cd30的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination